From GlobeNewswire: 2025-05-20 15:15:00

Diagnos Inc. announces the extension of the maturity date for $300,000 unsecured convertible debentures issued as part of a private placement to May 18, 2026. All other provisions of the debentures will remain unchanged during the extension period. An insider of the Corporation owns two debentures worth $100,000, representing 3.35% of the total issued common shares on a partially diluted basis. The Amendment is considered exempt from certain requirements of Multilateral Instrument 61-101. The board of directors has reviewed and approved the Amendment for the best interest of DIAGNOS and its shareholders. The Amendment is subject to TSX Venture Exchange acceptance and formal documentation execution. All monies quoted in the press release are stated and paid in lawful money of Canada. DIAGNOS is a Canadian corporation focusing on early detection of critical eye-related health issues using Artificial Intelligence.

For more information, visit www.diagnos.com and www.sedarplus.com. This news release contains forward-looking information, and there is no assurance that it will prove accurate. DIAGNOS disclaims any intention to publicly update or revise forward-looking information. The TSX Venture Exchange does not accept responsibility for the accuracy of this release.



Read more at GlobeNewswire: DIAGNOS Announces Amendment to Convertible Debentures